- The test, run on Abbott’s portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion
- The test produces lab-quality results in 15 minutes
- Clinicians are now able to get a result at the patient’s bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room
- The test can be used to help evaluate patients up to 24 hours after injury
Category Archives: AZBio News
AZBioPEERS – Maximizing Your Operational Efficiency
Don’t miss this opportunity to learn how Bio Business Solutions can drive efficiency and profitability for your bioscience business.Continue reading
What is OTEF?
You’ve probably heard of AZAdvances, but do you know about OTEF? The Opportunity Through Entrepreneurship Foundation (OTEF) is the the 501c3 public charity that houses AZAdvances. Continue reading
AZBio Member Anivive featured on the I am BIO Podcast
Biotech for our Pets: More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries.
Diagnostics in Life Sciences is the Key to Healthcare – An Interview with Mara Aspinall of Illumina Ventures – AZ
Mara Aspinall is a healthcare industry leader and pioneer with a commitment to civic involvement. She recently was interviewed on the AZ Tech Roundtable with Matt Battaglia. Continue reading
Longevity Scores Show Signs of Resilience to Certain Diseases
Polygenic scores calculated by TGen researchers reflect both long life and healthContinue reading
Taking a Closer Look at Pulmonary Fibrosis Genetics
Study is the first to map variations in gene regulation at the cell type level throughout the lung
C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research
TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early Continue reading